

Niklas Mattsson

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6647443/niklas-mattsson-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

272
papers

15,022
citations

62
h-index

115
g-index

311
ext. papers

19,929
ext. citations

7
avg, IF

6.7
L-index

| # | Paper | IF | Citations |
|-----|--|------|-----------|
| 272 | Central nervous system monoaminergic activity in hip osteoarthritis patients with disabling pain: associations with pain severity and central sensitization.. <i>Pain Reports</i> , 2022 , 7, e988 | 3.5 | 1 |
| 271 | Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum.. <i>JAMA Neurology</i> , 2022 , | 17.2 | 9 |
| 270 | □ <i>Neurology</i> , 2022 , | 6.5 | 3 |
| 269 | Components of gait in people with and without mild cognitive impairment.. <i>Gait and Posture</i> , 2022 , 93, 83-89 | 2.6 | |
| 268 | Serum neurofilament light levels are correlated to long-term neurocognitive outcome measures after cardiac arrest.. <i>Brain Injury</i> , 2022 , 1-10 | 2.1 | 0 |
| 267 | Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.. <i>JAMA Neurology</i> , 2021 , | 17.2 | 10 |
| 266 | Genetic effects on longitudinal cognitive decline during the early stages of Alzheimer's disease. <i>Scientific Reports</i> , 2021 , 11, 19853 | 4.9 | 0 |
| 265 | Association of Enlarged Perivascular Spaces and Measures of Small Vessel and Alzheimer Disease. <i>Neurology</i> , 2021 , 96, e193-e202 | 6.5 | 8 |
| 264 | Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment. <i>Alzheimer's Research and Therapy</i> , 2021 , 13, 68 | 9 | 35 |
| 263 | Early stages of tau pathology and its associations with functional connectivity, atrophy and memory. <i>Brain</i> , 2021 , 144, 2771-2783 | 11.2 | 10 |
| 262 | Perceived walking difficulties in Parkinson's disease - predictors and changes over time. <i>BMC Geriatrics</i> , 2021 , 21, 221 | 4.1 | 0 |
| 261 | A multicenter comparison of [F]flortaucipir, [F]RO948, and [F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 48, 2295-2305 | 8.8 | 11 |
| 260 | Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures. <i>Nature Medicine</i> , 2021 , 27, 1034-1042 | 50.5 | 56 |
| 259 | Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau. <i>EMBO Molecular Medicine</i> , 2021 , 13, e14022 | 12 | 22 |
| 258 | Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects. <i>Brain</i> , 2021 , 144, 2826-2836 | 11.2 | 12 |
| 257 | The BIN1 rs744373 Alzheimer's disease risk SNP is associated with faster Aβ-associated tau accumulation and cognitive decline. <i>Alzheimer's and Dementia</i> , 2021 , | 1.2 | 4 |
| 256 | Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ2/Aβ0 and p-tau. <i>Alzheimer's and Dementia</i> , 2021 , | 1.2 | 12 |

| | | | |
|-----|--|------|----|
| 255 | Plasma biomarkers of Alzheimer's disease improve prediction of cognitive decline in cognitively unimpaired elderly populations. <i>Nature Communications</i> , 2021 , 12, 3555 | 17.4 | 23 |
| 254 | Tau PET correlates with different Alzheimer's disease-related features compared to CSF and plasma p-tau biomarkers. <i>EMBO Molecular Medicine</i> , 2021 , 13, e14398 | 12 | 8 |
| 253 | The Effects of Tau, Amyloid, and White Matter Lesions on Mobility, Dual Tasking, and Balance in Older People. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021 , 76, 683-694 | 6.4 | 2 |
| 252 | Association Between Apolipoprotein E ϵ vs ϵ , Age, and ϵ Amyloid in Adults Without Cognitive Impairment. <i>JAMA Neurology</i> , 2021 , 78, 229-235 | 17.2 | 10 |
| 251 | Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations. <i>Nature Aging</i> , 2021 , 1, 114-123 | | 34 |
| 250 | Plasma phosphorylated tau181 and neurodegeneration in Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , 2021 , 8, 259-265 | 5.3 | 9 |
| 249 | Untangling the association of amyloid- β and tau with synaptic and axonal loss in Alzheimer's disease. <i>Brain</i> , 2021 , 144, 310-324 | 11.2 | 34 |
| 248 | Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease. <i>JAMA Neurology</i> , 2021 , 78, 149-156 | 17.2 | 62 |
| 247 | The impact of demographic, clinical, genetic, and imaging variables on tau PET status. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 48, 2245-2258 | 8.8 | 8 |
| 246 | Current advances in plasma and cerebrospinal fluid biomarkers in Alzheimer's disease. <i>Current Opinion in Neurology</i> , 2021 , 34, 266-274 | 7.1 | 14 |
| 245 | Mild behavioral impairment and its relation to tau pathology in preclinical Alzheimer's disease. <i>Translational Psychiatry</i> , 2021 , 11, 76 | 8.6 | 32 |
| 244 | Accelerated inflammatory aging in Alzheimer's disease and its relation to amyloid, tau, and cognition. <i>Scientific Reports</i> , 2021 , 11, 1965 | 4.9 | 9 |
| 243 | Time between milestone events in the Alzheimer's disease amyloid cascade. <i>NeuroImage</i> , 2021 , 227, 117676 | 7.9 | 5 |
| 242 | Preoperative sleep quality and adverse pain outcomes after total hip arthroplasty. <i>European Journal of Pain</i> , 2021 , 25, 1482-1492 | 3.7 | 5 |
| 241 | Plasma GFAP is an early marker of amyloid- β but not tau pathology in Alzheimer's disease. <i>Brain</i> , 2021 , | 11.2 | 31 |
| 240 | Serum markers of brain injury can predict good neurological outcome after out-of-hospital cardiac arrest. <i>Intensive Care Medicine</i> , 2021 , 47, 984-994 | 14.5 | 10 |
| 239 | Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging. <i>JAMA Neurology</i> , 2021 , 78, 961-971 | 17.2 | 29 |
| 238 | Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays. <i>Neurology</i> , 2021 , 97, e1681-e1694 | 6.5 | 10 |

| | | | |
|-----|--|------|-----|
| 237 | Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. <i>Lancet Neurology, The</i> , 2021 , 20, 739-752 | 24.1 | 43 |
| 236 | Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohorts. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 48, 2259-2271 | 8.8 | 4 |
| 235 | The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021 , 17, 1145-1156 | 1.2 | 48 |
| 234 | Association of CSF Aβ8 Levels With Risk of Alzheimer Disease-Related Decline.. <i>Neurology</i> , 2021 , | 6.5 | 2 |
| 233 | Blood-based biomarkers for Alzheimer's disease. <i>EMBO Molecular Medicine</i> , 2021 , e14408 | 12 | 7 |
| 232 | Genetic influence during the early phases of Alzheimer's disease on longitudinal cognitive impairment.. <i>Alzheimer's and Dementia</i> , 2021 , 17 Suppl 3, e053474 | 1.2 | |
| 231 | Genetic interaction study of Alzheimer's disease quantitative biomarkers: A polygenic risk score analysis and evaluation.. <i>Alzheimer's and Dementia</i> , 2021 , 17 Suppl 3, e053556 | 1.2 | |
| 230 | Comparison of 18F-Flortaucipir visual assessment, SUVR quantification and CSF pTau for defining T-status in the AT(N) framework. <i>Alzheimer's and Dementia</i> , 2020 , 16, e037276 | 1.2 | |
| 229 | White matter lesions are associated with CSF biomarkers of neuroinflammation in prodromal Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020 , 16, e041795 | 1.2 | |
| 228 | Mild behavioral impairment is predictive of tau deposition in the earliest stages of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020 , 16, e042595 | 1.2 | 3 |
| 227 | Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies. <i>Nature Communications</i> , 2020 , 11, 6252 | 17.4 | 15 |
| 226 | CDH6 and HAGH protein levels in plasma associate with Alzheimer's disease in APOE ε4 carriers. <i>Scientific Reports</i> , 2020 , 10, 8233 | 4.9 | 4 |
| 225 | Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders. <i>JAMA Neurology</i> , 2020 , 77, 955-965 | 17.2 | 71 |
| 224 | The implications of different approaches to define AT(N) in Alzheimer disease. <i>Neurology</i> , 2020 , 94, e2233-e2244 | 3.5 | 4 |
| 223 | Relevance of biomarkers across different neurodegenerative diseases. <i>Alzheimer's Research and Therapy</i> , 2020 , 12, 56 | 9 | 15 |
| 222 | Performance of a guideline-recommended algorithm for prognostication of poor neurological outcome after cardiac arrest. <i>Intensive Care Medicine</i> , 2020 , 46, 1852-1862 | 14.5 | 25 |
| 221 | Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia. <i>Nature Medicine</i> , 2020 , 26, 379-386 | 50.5 | 292 |
| 220 | Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course-a joint PhD student course at University College London and University of Gothenburg. <i>Alzheimer's Research and Therapy</i> , 2020 , 12, 20 | 9 | 13 |

| | | | |
|-----|--|------|-----|
| 219 | Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease. <i>Nature Communications</i> , 2020 , 11, 1683 | 17.4 | 133 |
| 218 | Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer's disease. <i>Science Advances</i> , 2020 , 6, eaaz2387 | 14.3 | 88 |
| 217 | Acute reduction of cerebrospinal fluid volume prior to spinal anesthesia: implications for sensory block extent. <i>Minerva Anestesiologica</i> , 2020 , 86, 636-644 | 1.9 | 2 |
| 216 | Serum GFAP and UCH-L1 for the prediction of neurological outcome in comatose cardiac arrest patients. <i>Resuscitation</i> , 2020 , 154, 61-68 | 4 | 12 |
| 215 | The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects. <i>Brain</i> , 2020 , 143, 3805-3815 | 11.2 | 18 |
| 214 | Cerebrospinal fluid levels of neurogranin in Parkinsonian disorders. <i>Movement Disorders</i> , 2020 , 35, 513-518 | 5.8 | 11 |
| 213 | Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease. <i>Brain</i> , 2020 , 143, 3234-3241 | 32.4 | 63 |
| 212 | Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 324, 772-781 | 27.4 | 268 |
| 211 | Comparing progression biomarkers in clinical trials of early Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , 2020 , 7, 1661-1673 | 5.3 | 14 |
| 210 | Differential expression of cerebrospinal fluid neuroinflammatory mediators depending on osteoarthritis pain phenotype. <i>Pain</i> , 2020 , 161, 2142-2154 | 8 | 6 |
| 209 | Apathy and anxiety are early markers of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2020 , 85, 74-82 | 5.6 | 50 |
| 208 | Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. <i>Lancet Neurology</i> , 2020 , 19, 422-433 | 24.1 | 286 |
| 207 | The A4 study: Aβ amyloid and cognition in 4432 cognitively unimpaired adults. <i>Annals of Clinical and Translational Neurology</i> , 2020 , 7, 776-785 | 5.3 | 15 |
| 206 | Utility of plasma neurofilament light and total tau for clinical trials in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020 , 12, e12099 | 5.2 | 8 |
| 205 | Predicting diagnosis and cognition with F-AV-1451 tau PET and structural MRI in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2019 , 15, 570-580 | 1.2 | 43 |
| 204 | Associations between partial pressure of oxygen and neurological outcome in out-of-hospital cardiac arrest patients: an explorative analysis of a randomized trial. <i>Critical Care</i> , 2019 , 23, 30 | 10.8 | 16 |
| 203 | Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis. <i>JAMA Neurology</i> , 2019 , 76, 1035-1048 | 17.2 | 237 |
| 202 | Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease-Related Aβ Amyloid Status. <i>JAMA Neurology</i> , 2019 , 76, 1060-1069 | 17.2 | 159 |

| | | | |
|-----|--|------|-----|
| 201 | Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease. <i>JAMA Neurology</i> , 2019 , 76, 791-799 | 17.2 | 228 |
| 200 | Serum tau fragments as predictors of death or poor neurological outcome after out-of-hospital cardiac arrest. <i>Biomarkers</i> , 2019 , 24, 584-591 | 2.6 | 2 |
| 199 | Cerebrospinal fluid neurofilament light is associated with survival in mitochondrial disease patients. <i>Mitochondrion</i> , 2019 , 46, 228-235 | 4.9 | 5 |
| 198 | βAmyloid pathology and hippocampal atrophy are independently associated with memory function in cognitively healthy elderly. <i>Scientific Reports</i> , 2019 , 9, 11180 | 4.9 | 15 |
| 197 | Determining clinically meaningful decline in preclinical Alzheimer disease. <i>Neurology</i> , 2019 , 93, e322-e335 | 3.5 | 40 |
| 196 | Staging βAmyloid Pathology With Amyloid Positron Emission Tomography. <i>JAMA Neurology</i> , 2019 , 76, 1319-1329 | 17.2 | 71 |
| 195 | Associations among amyloid status, age, and longitudinal regional brain atrophy in cognitively unimpaired older adults. <i>Neurobiology of Aging</i> , 2019 , 82, 110-119 | 5.6 | 4 |
| 194 | Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease. <i>EMBO Molecular Medicine</i> , 2019 , 11, e11170 | 12 | 113 |
| 193 | Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer's disease. <i>Acta Neuropathologica Communications</i> , 2019 , 7, 169 | 7.3 | 58 |
| 192 | P4-536: CEREBROSPINAL FLUID BIOMARKERS FOR AMYLOID AND TAU USING FULLY AUTOMATED ASSAYS: ASSOCIATIONS WITH NEUROPATHOLOGY 2019 , 15, P1521-P1521 | | |
| 191 | DT-01-04: DIAGNOSTIC PERFORMANCE OF [18F]RO948 PET IN THE SEPARATION OF ALZHEIMER'S DISEASE FROM OTHER NEURODEGENERATIVE DISORDERS: FINDINGS FROM THE BIOFINDER-2 STUDY 2019 , 15, P1485-P1486 | | |
| 190 | Predicting clinical decline and conversion to Alzheimer's disease or dementia using novel Elecsys Aβ(1-42), pTau and tTau CSF immunoassays. <i>Scientific Reports</i> , 2019 , 9, 19024 | 4.9 | 50 |
| 189 | Predictive Factors of Concerns about Falling in People with Parkinson's Disease: A 3-Year Longitudinal Study. <i>Parkinson's Disease</i> , 2019 , 2019, 4747320 | 2.6 | 6 |
| 188 | Associations between tau, Aβ and cortical thickness with cognition in Alzheimer disease. <i>Neurology</i> , 2019 , 92, e601-e612 | 6.5 | 125 |
| 187 | Data-driven approaches for tau-PET imaging biomarkers in Alzheimer's disease. <i>Human Brain Mapping</i> , 2019 , 40, 638-651 | 5.9 | 17 |
| 186 | Accurate risk estimation of βAmyloid positivity to identify prodromal Alzheimer's disease: Cross-validation study of practical algorithms. <i>Alzheimer's and Dementia</i> , 2019 , 15, 194-204 | 1.2 | 31 |
| 185 | Serum Neurofilament Light Chain for Prognosis of Outcome After Cardiac Arrest. <i>JAMA Neurology</i> , 2019 , 76, 64-71 | 17.2 | 85 |
| 184 | Biomarkers for tau pathology. <i>Molecular and Cellular Neurosciences</i> , 2019 , 97, 18-33 | 4.8 | 96 |

| | | | |
|-----|--|------|-----|
| 183 | The National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease: Perspectives from the Research Roundtable. <i>Alzheimer's and Dementia</i> , 2018 , 14, 563-575 | 1.2 | 61 |
| 182 | Amyloid pathology in the progression to mild cognitive impairment. <i>Neurobiology of Aging</i> , 2018 , 64, 76-84 | 5.6 | 17 |
| 181 | Comparing F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease. <i>Neurology</i> , 2018 , 90, e388-e395 | 6.5 | 62 |
| 180 | Prevalence of the apolipoprotein E ϵ allele in amyloid τ positive subjects across the spectrum of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018 , 14, 913-924 | 1.2 | 36 |
| 179 | Fluid Biomarkers in Alzheimer's Disease and Frontotemporal Dementia 2018 , 221-252 | | 1 |
| 178 | Apolipoprotein E genotypes and longevity across dementia disorders. <i>Alzheimer's and Dementia</i> , 2018 , 14, 895-901 | 1.2 | 6 |
| 177 | Chronic depressive symptomatology and CSF amyloid beta and tau levels in mild cognitive impairment. <i>International Journal of Geriatric Psychiatry</i> , 2018 , 33, 1305-1311 | 3.9 | 11 |
| 176 | The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review. <i>Alzheimer's and Dementia</i> , 2018 , 14, 1313-1333 | 1.2 | 61 |
| 175 | CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease. <i>Neurology</i> , 2018 , 91, e867-e877 | 6.5 | 120 |
| 174 | Effects of APOE ϵ on neuroimaging, cerebrospinal fluid biomarkers, and cognition in prodromal Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018 , 71, 81-90 | 5.6 | 8 |
| 173 | Greater tau load and reduced cortical thickness in APOE ϵ -negative Alzheimer's disease: a cohort study. <i>Alzheimer's Research and Therapy</i> , 2018 , 10, 77 | 9 | 36 |
| 172 | Carbon dioxide dynamics in relation to neurological outcome in resuscitated out-of-hospital cardiac arrest patients: an exploratory Target Temperature Management Trial substudy. <i>Critical Care</i> , 2018 , 22, 196 | 10.8 | 20 |
| 171 | Association of Cerebral Amyloid- τ Aggregation With Cognitive Functioning in Persons Without Dementia. <i>JAMA Psychiatry</i> , 2018 , 75, 84-95 | 14.5 | 94 |
| 170 | P1-279: BIMODAL DISTRIBUTION OF THE CSF A β ₂ /A β ₀ RATIO IN CLINICAL LABORATORY PRACTICE 2018 , 14, P389-P390 | | |
| 169 | DT-01-06: COGNITIVE DECLINE IN PRECLINICAL ALZHEIMER'S DISEASE: A COMPARISON AND SYNTHESIS OF LARGE INTERNATIONAL COHORTS 2018 , 14, P1667-P1668 | | |
| 168 | P1-430: EFFECTS OF APOE ϵ ON TAU, AMYLOID, ATROPHY AND COGNITION IN ALZHEIMER'S DISEASE 2018 , 14, P473-P474 | | |
| 167 | DT-01-01: DEVELOPMENT OF AB, TAU AND COGNITIVE CHANGES DURING THE TIME COURSE OF SPORADIC ALZHEIMER'S DISEASE 2018 , 14, P1665-P1665 | | |
| 166 | DT-02-04: DETECTING BRAIN AMYLOID STATUS USING FULLY AUTOMATED PLASMA A β BIOMARKER ASSAYS 2018 , 14, P1670-P1670 | | 1 |

| | | | |
|-----|--|------|-----|
| 165 | Prevalence of amyloid- β pathology in distinct variants of primary progressive aphasia. <i>Annals of Neurology</i> , 2018 , 84, 729-740 | 9.4 | 74 |
| 164 | Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders. <i>JAMA - Journal of the American Medical Association</i> , 2018 , 320, 1151-1162 | 27.4 | 173 |
| 163 | Cerebrospinal fluid neurofilament light concentration in motor neuron disease and frontotemporal dementia predicts survival. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2017 , 18, 397-403 | 3.6 | 49 |
| 162 | Cortical Atrophy is Associated with Accelerated Cognitive Decline in Mild Cognitive Impairment with Subsyndromal Depression. <i>American Journal of Geriatric Psychiatry</i> , 2017 , 25, 980-991 | 6.5 | 21 |
| 161 | Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease. <i>JAMA Neurology</i> , 2017 , 74, 557-566 | 17.2 | 435 |
| 160 | Clinical validity of cerebrospinal fluid A β 2, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. <i>Neurobiology of Aging</i> , 2017 , 52, 196-213 | 5.6 | 73 |
| 159 | Earliest accumulation of β amyloid occurs within the default-mode network and concurrently affects brain connectivity. <i>Nature Communications</i> , 2017 , 8, 1214 | 17.4 | 348 |
| 158 | Serum tau and neurological outcome in cardiac arrest. <i>Annals of Neurology</i> , 2017 , 82, 665-675 | 9.4 | 55 |
| 157 | A novel quantification-driven proteomic strategy identifies an endogenous peptide of pleiotrophin as a new biomarker of Alzheimer's disease. <i>Scientific Reports</i> , 2017 , 7, 13333 | 4.9 | 33 |
| 156 | [O2D5D5]: EFFECTS OF APOE E4 IN PRODROMAL ALZHEIMER'S DISEASE 2017 , 13, P562-P563 | | |
| 155 | Effects of surgery and propofol-remifentanyl total intravenous anesthesia on cerebrospinal fluid biomarkers of inflammation, Alzheimer's disease, and neuronal injury in humans: a cohort study. <i>Journal of Neuroinflammation</i> , 2017 , 14, 193 | 10.1 | 9 |
| 154 | Preclinical effects of APOE ϵ 4 on cerebrospinal fluid A β 2 concentrations. <i>Alzheimer's Research and Therapy</i> , 2017 , 9, 87 | 9 | 16 |
| 153 | CSF/serum albumin ratio in dementias: a cross-sectional study on 1861 patients. <i>Neurobiology of Aging</i> , 2017 , 59, 1-9 | 5.6 | 52 |
| 152 | F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer's disease. <i>EMBO Molecular Medicine</i> , 2017 , 9, 1212-1223 | 12 | 124 |
| 151 | Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. <i>Lancet Neurology</i> , 2017 , 16, 661-676 | 24.1 | 308 |
| 150 | Ex vivo O-labeling mass spectrometry identifies a peripheral amyloid β clearance pathway. <i>Molecular Neurodegeneration</i> , 2017 , 12, 18 | 19 | 15 |
| 149 | Multiple comorbid neuropathologies in the setting of Alzheimer's disease neuropathology and implications for drug development. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017 , 3, 83-91 | 6 | 57 |
| 148 | [P3D32]: CSF BIOMARKERS OF NEUROINFLAMMATION ARE ELEVATED IN PRECLINICAL AND PRODROMAL AD AND CORRELATE WITH TAU PATHOLOGY 2017 , 13, P985-P985 | | |

| | | | |
|-----|---|------|-----|
| 147 | [P4197]: EMERGING AMYLOID PATHOLOGY 2017 , 13, P1340-P1340 | | |
| 146 | [P1875]: PREVALENCE OF THE APOLIPOPROTEIN E ϵ 4 ALLELE IN AMYLOID-POSITIVE SUBJECTS ACROSS THE SPECTRUM OF ALZHEIMER'S DISEASE 2017 , 13, P515-P515 | | |
| 145 | [P3075]: PLEIOTROPHIN, A NEW BIOMARKER FOR AD, IDENTIFIED USING A NOVEL STRATEGY IN CLINICAL PROTEOMICS 2017 , 13, P960-P961 | | |
| 144 | Time to Amyloid Positivity and Preclinical Changes in Brain Metabolism, Atrophy, and Cognition: Evidence for Emerging Amyloid Pathology in Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 2017 , 11, 281 | 5.1 | 47 |
| 143 | Interaction of Cigarette Smoking History With APOE Genotype and Age on Amyloid Level, Glucose Metabolism, and Neurocognition in Cognitively Normal Elders. <i>Nicotine and Tobacco Research</i> , 2016 , 18, 204-11 | 4.9 | 27 |
| 142 | Assessing risk for preclinical β amyloid pathology with , cognitive, and demographic information. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016 , 4, 76-84 | 5.2 | 36 |
| 141 | Increased amyloidogenic APP processing in APOE e4-negative individuals with cerebral β amyloidosis. <i>Nature Communications</i> , 2016 , 7, 10918 | 17.4 | 39 |
| 140 | Serum neurofilament light protein predicts clinical outcome in traumatic brain injury. <i>Scientific Reports</i> , 2016 , 6, 36791 | 4.9 | 186 |
| 139 | Cerebrospinal fluid A β 2/A β 0 and A β 2/A β 8 as biomarkers of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2016 , 39, S28 | 5.6 | 3 |
| 138 | Chronic Depressive Symptomatology in Mild Cognitive Impairment Is Associated with Frontal Atrophy Rate which Hastens Conversion to Alzheimer Dementia. <i>American Journal of Geriatric Psychiatry</i> , 2016 , 24, 126-35 | 6.5 | 42 |
| 137 | CSF A β 2/A β 0 and A β 2/A β 8 ratios: better diagnostic markers of Alzheimer disease. <i>Annals of Clinical and Translational Neurology</i> , 2016 , 3, 154-65 | 5.3 | 244 |
| 136 | Total-tau and neurofilament light in CSF reflect spinal cord ischaemia after endovascular aortic repair. <i>Neurochemistry International</i> , 2016 , 93, 1-5 | 4.4 | 11 |
| 135 | Selective vulnerability in neurodegeneration: insights from clinical variants of Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 1000-4 | 5.5 | 50 |
| 134 | Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression. <i>JAMA Neurology</i> , 2016 , 73, 60-7 | 17.2 | 258 |
| 133 | Reply: Do we still need positron emission tomography for early Alzheimer's disease diagnosis?. <i>Brain</i> , 2016 , 139, e61 | 11.2 | 4 |
| 132 | Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease. <i>EMBO Molecular Medicine</i> , 2016 , 8, 1184-1196 | 12 | 152 |
| 131 | P4-339: Early- and Late-Onset Alzheimer's Disease are Associated with Distinct Regional TAU Pathology as Examined with [18]F-AV-1451 TAU Positron Emission Tomography 2016 , 12, P1164-P1165 | | |
| 130 | P2-167: Roadmap to the Biomarker-Based Diagnosis of Alzheimer's Disease 2016 , 12, P679-P680 | | |

| | | | |
|-----|---|------|-----|
| 129 | O1-05-01: Increased Amyloidogenic app Processing in Apoe E4-Negative Individuals with Cerebral B-Amyloidosis 2016 , 12, P182-P182 | | |
| 128 | IC-P-002: : Roadmap to The Biomarker-Based Diagnosis of Alzheimer's Disease 2016 , 12, P13-P13 | | |
| 127 | P2-142: Comparison of T-Tau, Neurogranin and NFL as CSF Neurodegeneration Markers in Alzheimer's Disease 2016 , 12, P667-P667 | | |
| 126 | Cerebrospinal fluid analysis detects cerebral amyloid- β accumulation earlier than positron emission tomography. <i>Brain</i> , 2016 , 139, 1226-36 | 11.2 | 229 |
| 125 | Accelerating rates of cognitive decline and imaging markers associated with β amyloid pathology. <i>Neurology</i> , 2016 , 86, 1887-96 | 6.5 | 37 |
| 124 | Cognitive and functional changes associated with A β pathology and the progression to mild cognitive impairment. <i>Neurobiology of Aging</i> , 2016 , 48, 172-181 | 5.6 | 22 |
| 123 | Plasma tau in Alzheimer disease. <i>Neurology</i> , 2016 , 87, 1827-1835 | 6.5 | 269 |
| 122 | Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015 , 36, 2340-7 | 5.6 | 40 |
| 121 | Cerebrospinal fluid tau and amyloid- β 42 in patients with dementia. <i>Brain</i> , 2015 , 138, 2716-31 | 11.2 | 105 |
| 120 | Benchmarking biomarker-based criteria for Alzheimer's disease: Data from the Swedish Dementia Registry, SveDem. <i>Alzheimers and Dementia</i> , 2015 , 11, 1470-1479 | 1.2 | 12 |
| 119 | Magnetic resonance imaging in Alzheimer's Disease Neuroimaging Initiative 2. <i>Alzheimers and Dementia</i> , 2015 , 11, 740-56 | 1.2 | 101 |
| 118 | Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 313, 1924-38 | 27.4 | 842 |
| 117 | Predicting Reduction of Cerebrospinal Fluid β Amyloid 42 in Cognitively Healthy Controls. <i>JAMA Neurology</i> , 2015 , 72, 554-60 | 17.2 | 39 |
| 116 | The transitional association between β amyloid pathology and regional brain atrophy. <i>Alzheimers and Dementia</i> , 2015 , 11, 1171-9 | 1.2 | 29 |
| 115 | CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large-scale international multicenter study. <i>Alzheimers and Dementia</i> , 2015 , 11, 1306-15 | 1.2 | 87 |
| 114 | Amyloid biomarkers in Alzheimer's disease. <i>Trends in Pharmacological Sciences</i> , 2015 , 36, 297-309 | 13.2 | 320 |
| 113 | Serum visinin-like protein-1 in concussed professional ice hockey players. <i>Brain Injury</i> , 2015 , 29, 872-6 | 2.1 | 15 |
| 112 | Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. <i>Neurology</i> , 2015 , 85, 1240-9 | 6.5 | 192 |

| | | | |
|-----|--|------|-----|
| 111 | Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease. <i>Brain</i> , 2015 , 138, 3373-85 | 11.2 | 165 |
| 110 | Cerebrospinal fluid β -synuclein and Lewy body-like symptoms in normal controls, mild cognitive impairment, and Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2015 , 43, 1007-16 | 4.3 | 25 |
| 109 | Biomarkers and cognitive endpoints to optimize trials in Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , 2015 , 2, 534-47 | 5.3 | 25 |
| 108 | Revolutionizing Alzheimer's disease and clinical trials through biomarkers. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015 , 1, 412-9 | 5.2 | 66 |
| 107 | S5-01-03: CSF biomarkers versus PET biomarkers 2015 , 11, P302-P302 | | |
| 106 | Independent information from cerebrospinal fluid amyloid- β and florbetapir imaging in Alzheimer's disease. <i>Brain</i> , 2015 , 138, 772-83 | 11.2 | 169 |
| 105 | Brain structure and function as mediators of the effects of amyloid on memory. <i>Neurology</i> , 2015 , 84, 1136-44 | 6.5 | 33 |
| 104 | Understanding the cause of sporadic Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2014 , 14, 621-30 | 4.3 | 31 |
| 103 | Cerebrospinal fluid biomarkers of β -amyloid metabolism and neuronal damage in epileptic seizures. <i>European Journal of Neurology</i> , 2014 , 21, 486-91 | 6 | 16 |
| 102 | Lysosomal network proteins as potential novel CSF biomarkers for Alzheimer's disease. <i>NeuroMolecular Medicine</i> , 2014 , 16, 150-60 | 4.6 | 65 |
| 101 | Assessment of peptide chemical modifications on the development of an accurate and precise multiplex selected reaction monitoring assay for apolipoprotein e isoforms. <i>Journal of Proteome Research</i> , 2014 , 13, 1077-87 | 5.6 | 41 |
| 100 | CSF in Alzheimer's disease. <i>Advances in Clinical Chemistry</i> , 2014 , 65, 143-72 | 5.8 | 18 |
| 99 | History of cigarette smoking in cognitively-normal elders is associated with elevated cerebrospinal fluid biomarkers of oxidative stress. <i>Drug and Alcohol Dependence</i> , 2014 , 142, 262-8 | 4.9 | 21 |
| 98 | Association of brain amyloid- β with cerebral perfusion and structure in Alzheimer's disease and mild cognitive impairment. <i>Brain</i> , 2014 , 137, 1550-61 | 11.2 | 109 |
| 97 | Altered cerebrospinal fluid levels of amyloid β and amyloid precursor-like protein 1 peptides in Down's syndrome. <i>NeuroMolecular Medicine</i> , 2014 , 16, 510-6 | 4.6 | 26 |
| 96 | The cerebrospinal fluid "Alzheimer profile": easily said, but what does it mean?. <i>Alzheimer's and Dementia</i> , 2014 , 10, 713-723.e2 | 1.2 | 204 |
| 95 | Automated cerebrospinal fluid cell count--new reference ranges and evaluation of its clinical use in central nervous system infections. <i>Clinical Biochemistry</i> , 2014 , 47, 25-30 | 3.5 | 21 |
| 94 | Effects of cerebrospinal fluid proteins on brain atrophy rates in cognitively healthy older adults. <i>Neurobiology of Aging</i> , 2014 , 35, 614-22 | 5.6 | 36 |

| | | | |
|----|---|------|-----|
| 93 | Smoking and increased Alzheimer's disease risk: a review of potential mechanisms. <i>Alzheimer's and Dementia</i> , 2014 , 10, S122-45 | 1.2 | 194 |
| 92 | Bidirectional links between Alzheimer's disease and Niemann-Pick type C disease. <i>Neurobiology of Disease</i> , 2014 , 72 Pt A, 37-47 | 7.5 | 59 |
| 91 | CSF biomarkers for Alzheimer's pathology and the effect size of APOE e4. <i>Molecular Psychiatry</i> , 2014 , 19, 148-9 | 15.1 | 26 |
| 90 | P4-137: THE TRANSITIONAL ASSOCIATION BETWEEN BETA-AMYLOID PATHOLOGY AND REGIONAL BRAIN ATROPHY 2014 , 10, P837-P838 | | 3 |
| 89 | Bite amyloid precursor protein-cleaving enzyme 1 (BACE1) inhibitor treatment induces Aβ-X peptides through alternative amyloid precursor protein cleavage. <i>Alzheimer's Research and Therapy</i> , 2014 , 6, 75 | 9 | 28 |
| 88 | Reporting standards for studies of diagnostic test accuracy in dementia: The STARDdem Initiative. <i>Neurology</i> , 2014 , 83, 364-73 | 6.5 | 146 |
| 87 | Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , 2014 , 1, 534-43 | 5.3 | 78 |
| 86 | Exploring Alzheimer molecular pathology in Down's syndrome cerebrospinal fluid. <i>Neurodegenerative Diseases</i> , 2014 , 14, 98-106 | 2.3 | 36 |
| 85 | Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease. <i>JAMA Psychiatry</i> , 2014 , 71, 1183-91 | 14.5 | 65 |
| 84 | Diagnostic performance of cerebrospinal fluid total tau and phosphorylated tau in Creutzfeldt-Jakob disease: results from the Swedish Mortality Registry. <i>JAMA Neurology</i> , 2014 , 71, 476-83 | 17.2 | 125 |
| 83 | Emerging β-amyloid pathology and accelerated cortical atrophy. <i>JAMA Neurology</i> , 2014 , 71, 725-34 | 17.2 | 43 |
| 82 | CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival. <i>Neurology</i> , 2014 , 83, 1945-53 | 6.5 | 186 |
| 81 | Cerebrospinal Fluid Biomarkers in Alzheimer's Disease and Frontotemporal Dementia 2014 , 131-157 | | |
| 80 | The influence of disease duration, clinical course, and immunosuppressive therapy on the synthesis of intrathecal oligoclonal IgG bands in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2013 , 264, 100-5 | 3.5 | 26 |
| 79 | CSF biomarker variability in the Alzheimer's Association quality control program. <i>Alzheimer's and Dementia</i> , 2013 , 9, 251-61 | 1.2 | 289 |
| 78 | Serum but not cerebrospinal fluid levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) are increased in Alzheimer's disease. <i>Psychoneuroendocrinology</i> , 2013 , 38, 1729-37 | 5 | 51 |
| 77 | Coagulation of cerebrospinal fluid--the Nonne-Froin sign. <i>Practical Neurology</i> , 2013 , 13, 273-4 | 2.4 | 1 |
| 76 | Cerebrospinal fluid biomarkers in neurological diseases in children. <i>European Journal of Paediatric Neurology</i> , 2013 , 17, 7-13 | 3.8 | 15 |

| | | | |
|----|--|-----|-----|
| 75 | Cerebrospinal fluid brain injury biomarkers in children: a multicenter study. <i>Pediatric Neurology</i> , 2013 , 49, 31-39.e2 | 2.9 | 25 |
| 74 | Reduced cerebrospinal fluid level of thyroxine in patients with Alzheimer's disease. <i>Psychoneuroendocrinology</i> , 2013 , 38, 1058-66 | 5 | 30 |
| 73 | Cerebrospinal fluid CXCL13 in Lyme neuroborreliosis and asymptomatic HIV infection. <i>BMC Neurology</i> , 2013 , 13, 2 | 3.1 | 38 |
| 72 | Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: an update from the Alzheimer's Association Global Biomarkers Consortium. <i>Alzheimer's and Dementia</i> , 2013 , 9, 137-40 | 1.2 | 93 |
| 71 | Cerebrospinal fluid biomarkers of β amyloid metabolism in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 543-52 | 5 | 37 |
| 70 | Serum levels of LIGHT in MS. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 871-6 | 5 | 14 |
| 69 | Cerebrospinal fluid analyses for the diagnosis of subarachnoid haemorrhage and experience from a Swedish study. What method is preferable when diagnosing a subarachnoid haemorrhage?. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013 , 51, 2073-86 | 5.9 | 29 |
| 68 | CSF protein biomarkers predicting longitudinal reduction of CSF β amyloid42 in cognitively healthy elders. <i>Translational Psychiatry</i> , 2013 , 3, e293 | 8.6 | 37 |
| 67 | Cerebrospinal fluid biomarkers for Alzheimer disease and subcortical axonal damage in 5,542 clinical samples. <i>Alzheimer's Research and Therapy</i> , 2013 , 5, 47 | 9 | 31 |
| 66 | Plasma amyloid- β in patients with Tangier disease. <i>Journal of Alzheimer's Disease</i> , 2013 , 35, 307-12 | 4.3 | 3 |
| 65 | Journal Watch: Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of neurodegenerative disease management. <i>Neurodegenerative Disease Management</i> , 2013 , 3, 105-107 | 2.8 | |
| 64 | Journal Watch: Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of neurodegenerative disease management.. <i>Neurodegenerative Disease Management</i> , 2013 , 3, 19-21 | 2.8 | |
| 63 | Cerebrospinal fluid (CSF) 25-hydroxyvitamin D concentration and CSF acetylcholinesterase activity are reduced in patients with Alzheimer's disease. <i>PLoS ONE</i> , 2013 , 8, e81989 | 3.7 | 36 |
| 62 | Effects of baseline CSF β synuclein on regional brain atrophy rates in healthy elders, mild cognitive impairment and Alzheimer's disease. <i>PLoS ONE</i> , 2013 , 8, e85443 | 3.7 | 11 |
| 61 | Mass spectrometric characterization of amyloid- β species in the 7PA2 cell model of Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2013 , 33, 85-93 | 4.3 | 44 |
| 60 | Age and diagnostic performance of Alzheimer disease CSF biomarkers. <i>Neurology</i> , 2012 , 78, 468-76 | 6.5 | 133 |
| 59 | Amyloid- β metabolism in Niemann-Pick C disease models and patients. <i>Metabolic Brain Disease</i> , 2012 , 27, 573-85 | 3.9 | 35 |
| 58 | Determining cut-points for Alzheimer's disease biomarkers: statistical issues, methods and challenges. <i>Biomarkers in Medicine</i> , 2012 , 6, 391-400 | 2.3 | 45 |

| | | | |
|----|---|-----|----|
| 57 | Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β . <i>Biomarkers in Medicine</i> , 2012 , 6, 409-17 | 2.3 | 66 |
| 56 | Proficiency testing programs for Alzheimer's disease cerebrospinal fluid biomarkers. <i>Biomarkers in Medicine</i> , 2012 , 6, 401-7 | 2.3 | 20 |
| 55 | Peptidome analysis of cerebrospinal fluid by LC-MALDI MS. <i>PLoS ONE</i> , 2012 , 7, e42555 | 3.7 | 48 |
| 54 | An online nano-LC-ESI-FTICR-MS method for comprehensive characterization of endogenous fragments from amyloid β and amyloid precursor protein in human and cat cerebrospinal fluid. <i>Journal of Mass Spectrometry</i> , 2012 , 47, 591-603 | 2.2 | 64 |
| 53 | Cerebrospinal fluid biomarkers to monitor treatment effects in Alzheimer's disease and related conditions. <i>Neurodegenerative Disease Management</i> , 2012 , 2, 117-123 | 2.8 | |
| 52 | Cerebrospinal fluid profiles of amyloid β -related biomarkers in Alzheimer's disease. <i>NeuroMolecular Medicine</i> , 2012 , 14, 65-73 | 4.6 | 61 |
| 51 | Leukocyte telomere length (LTL) is reduced in stable mild cognitive impairment but low LTL is not associated with conversion to Alzheimer's disease: a pilot study. <i>Experimental Gerontology</i> , 2012 , 47, 179-82 | 4.5 | 35 |
| 50 | Miglustat treatment may reduce cerebrospinal fluid levels of the axonal degeneration marker tau in niemann-pick type C. <i>JIMD Reports</i> , 2012 , 3, 45-52 | 1.9 | 19 |
| 49 | The Accu-Chek Mobile blood glucose monitoring system used under controlled conditions meets ISO 15197 standards in the hands of diabetes patients. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2012 , 72, 374-9 | 2 | 8 |
| 48 | What is a certified reference material?. <i>Biomarkers in Medicine</i> , 2012 , 6, 369-70 | 2.3 | 9 |
| 47 | Journal Watch: Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of neurodegenerative disease management. <i>Neurodegenerative Disease Management</i> , 2012 , 2, 451-453 | 2.8 | |
| 46 | Journal Watch: Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of neurodegenerative disease management. <i>Neurodegenerative Disease Management</i> , 2012 , 2, 569-572 | 2.8 | |
| 45 | Journal Watch: Our experts highlight the most important research articles across the spectrum of topics relevant to the field of neurodegenerative disease management. <i>Neurodegenerative Disease Management</i> , 2012 , 2, 351-354 | 2.8 | 1 |
| 44 | Longitudinal cerebrospinal fluid biomarkers over four years in mild cognitive impairment. <i>Journal of Alzheimer's Disease</i> , 2012 , 30, 767-78 | 4.3 | 62 |
| 43 | BACE1 inhibition induces a specific cerebrospinal fluid β -amyloid pattern that identifies drug effects in the central nervous system. <i>PLoS ONE</i> , 2012 , 7, e31084 | 3.7 | 60 |
| 42 | CSF biomarkers in neurodegenerative diseases. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011 , 49, 345-52 | 5.9 | 42 |
| 41 | Gamma-secretase-dependent amyloid-beta is increased in Niemann-Pick type C: a cross-sectional study. <i>Neurology</i> , 2011 , 76, 366-72 | 6.5 | 58 |
| 40 | The N-terminal domain of β -dystroglycan, released as a 38 kDa protein, is increased in cerebrospinal fluid in patients with Lyme neuroborreliosis. <i>Biochemical and Biophysical Research Communications</i> , 2011 , 412, 494-9 | 3.4 | 9 |

| | | | |
|----|---|-----|-----|
| 39 | The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. <i>Alzheimer's and Dementia</i> , 2011 , 7, 386-395.e6 | 1.2 | 291 |
| 38 | Biomarkers for microglial activation in Alzheimer's disease. <i>International Journal of Alzheimer's Disease</i> , 2011 , 2011, 939426 | 3.7 | 18 |
| 37 | Discriminatory Analysis of Biochip-Derived Protein Patterns in CSF and Plasma in Neurodegenerative Diseases. <i>Frontiers in Aging Neuroscience</i> , 2011 , 3, 1 | 5.3 | 53 |
| 36 | Novel aβ isoforms in Alzheimer's disease - their role in diagnosis and treatment. <i>Current Pharmaceutical Design</i> , 2011 , 17, 2594-602 | 3.3 | 60 |
| 35 | Cerebrospinal fluid biomarkers for Alzheimer's disease: diagnostic performance in a homogeneous mono-center population. <i>Journal of Alzheimer's Disease</i> , 2011 , 24, 537-46 | 4.3 | 62 |
| 34 | Mild dementia is associated with increased adrenal secretion of cortisol and precursor sex steroids in women. <i>Clinical Endocrinology</i> , 2011 , 75, 301-8 | 3.4 | 8 |
| 33 | Cerebrospinal fluid microglial markers in Alzheimer's disease: elevated chitotriosidase activity but lack of diagnostic utility. <i>NeuroMolecular Medicine</i> , 2011 , 13, 151-9 | 4.6 | 89 |
| 32 | Found in translation: a blood-based test for Niemann-Pick type C1. <i>Biomarkers in Medicine</i> , 2011 , 5, 201 | 2.3 | |
| 31 | A new member in the biomarker discovery toolbox. <i>Biomarkers in Medicine</i> , 2011 , 5, 202 | 2.3 | |
| 30 | Troponin T: more than acute myocardial infarction. <i>Biomarkers in Medicine</i> , 2011 , 5, 203 | 2.3 | |
| 29 | Growth factors in Parkinson's disease. <i>Biomarkers in Medicine</i> , 2011 , 5, 201-2 | 2.3 | |
| 28 | It is all about clearance. <i>Biomarkers in Medicine</i> , 2011 , 5, 202 | 2.3 | |
| 27 | To know or not to know: ethical issues related to early diagnosis of Alzheimer's disease. <i>International Journal of Alzheimer's Disease</i> , 2010 , 2010, | 3.7 | 36 |
| 26 | Cerebrospinal fluid analysis should be considered in patients with cognitive problems. <i>International Journal of Alzheimer's Disease</i> , 2010 , 2010, 163065 | 3.7 | 6 |
| 25 | Converging pathways of chromogranin and amyloid metabolism in the brain. <i>Journal of Alzheimer's Disease</i> , 2010 , 20, 1039-49 | 4.3 | 17 |
| 24 | Lessons from Multicenter Studies on CSF Biomarkers for Alzheimer's Disease. <i>International Journal of Alzheimer's Disease</i> , 2010 , 2010, | 3.7 | 20 |
| 23 | Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall. <i>Clinical Chemistry and Laboratory Medicine</i> , 2010 , 48, 603-7 | 5.9 | 60 |
| 22 | Neuroinflammation in Lyme neuroborreliosis affects amyloid metabolism. <i>BMC Neurology</i> , 2010 , 10, 51 | 3.1 | 36 |

| | | | |
|----|---|------|-----|
| 21 | Converging molecular pathways in human neural development and degeneration. <i>Neuroscience Research</i> , 2010 , 66, 330-2 | 2.9 | 29 |
| 20 | Proteomic profiling of cerebrospinal fluid in parkinsonian disorders. <i>Parkinsonism and Related Disorders</i> , 2010 , 16, 545-9 | 3.6 | 36 |
| 19 | Biochemical markers in Alzheimer's disease clinical trials. <i>Biomarkers in Medicine</i> , 2010 , 4, 91-8 | 2.3 | 12 |
| 18 | Use of theragnostic markers to select drugs for phase II/III trials for Alzheimer disease. <i>Alzheimer's Research and Therapy</i> , 2010 , 2, 32 | 9 | 12 |
| 17 | Future screening for incipient Alzheimer's disease--the influence of prevalence on test performance. <i>European Neurology</i> , 2009 , 62, 200-3 | 2.1 | 11 |
| 16 | Elevated cerebrospinal fluid levels of prostaglandin E2 and 15-(S)-hydroxyeicosatetraenoic acid in multiple sclerosis. <i>Journal of Internal Medicine</i> , 2009 , 265, 459-64 | 10.8 | 21 |
| 15 | CSF biomarkers: pinpointing Alzheimer pathogenesis. <i>Annals of the New York Academy of Sciences</i> , 2009 , 1180, 28-35 | 6.5 | 54 |
| 14 | Reduced cerebrospinal fluid BACE1 activity in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2009 , 15, 448-54 | 54 | 52 |
| 13 | CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. <i>JAMA - Journal of the American Medical Association</i> , 2009 , 302, 385-93 | 27.4 | 758 |
| 12 | Novel cerebrospinal fluid biomarkers of axonal degeneration in frontotemporal dementia. <i>Molecular Medicine Reports</i> , 2008 , 1, 757-61 | 2.9 | 24 |
| 11 | Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years. <i>Journal of Alzheimer's Disease</i> , 2007 , 12, 255-60 | 4.3 | 105 |
| 10 | Cerebrospinal fluid concentrations of peptides derived from chromogranin B and secretogranin II are decreased in multiple sclerosis. <i>Journal of Neurochemistry</i> , 2007 , 103, 1932-9 | 6 | 25 |
| 9 | Elevated cerebrospinal fluid F2-isoprostane levels indicating oxidative stress in healthy siblings of multiple sclerosis patients. <i>Neuroscience Letters</i> , 2007 , 414, 233-6 | 3.3 | 32 |
| 8 | Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial. <i>Alimentary Pharmacology and Therapeutics</i> , 2006 , 24, 945-54 | 6.1 | 120 |
| 7 | Plasma amyloid, phosphorylated tau, and neurofilament light for individualized risk prediction in mild cognitive impairment | | 1 |
| 6 | Data-driven approaches for Tau-PET imaging biomarkers in Alzheimer's disease | | 1 |
| 5 | Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease | | 1 |
| 4 | Time between milestone events in the Alzheimer's disease amyloid cascade | | 1 |

- 3 Plasma glial fibrillary acidic protein is an early marker of A β pathology in Alzheimer's disease 2
- 2 CSF A β 8 levels are associated with Alzheimer-related decline: implications for B-secretase modulators 1
- 1 Plasma biomarkers of Alzheimer's disease predict cognitive decline and could improve clinical trials in the cognitively unimpaired elderly 1